Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Data presented on first cloned, double knock-out miniature swine

15.01.2003


Important goal achieved in potential animal-to-human organ transplantation



In a session today at the annual meeting of the International Embryo Transfer Society (IETS), Randall Prather, Ph.D., Distinguished Professor of Reproductive Biotechnology at the University of Missouri-Columbia, announced the successful cloning of the first miniature swine with both copies of a specific gene "knocked out" of its DNA. The ultimate goal of this research, which is being conducted in partnership with Immerge BioTherapeutics, Inc (a BioTransplant Incorporated (Nasdaq:BTRN)/Novartis Pharma AG (NYSE:NYS) joint venture company), is to develop a herd of miniature swine that can be used as a safe source for human transplantation, a process known as xenotransplantation.

"The fact that we have been able to clone this particular strain of miniature swine with both copies of the gene that produces GGTA1 knocked out is a very exciting step for the field of xenotransplantation," said Dr. Prather, a researcher in MU’s College of Agriculture, Food and Natural Resources. "Organs from regular swine are too large for human transplant, and this particular strain of miniature swine has been refined for years solely for its potential use in humans."


New options for organ sources are desperately needed to treat the rapidly increasing number of critically ill people on the transplant waiting list (more than 80,000 in the U.S. alone). Researchers have targeted the pig as the best potential candidate for an alternative organ source because of the similarity between human and pig organs and the relative ease of breeding. However, the massive rejection response mounted by the human immune system has been a major hurdle in this research.

A key player in this rejection process is the gene called a-1,3-galactosyltransferase or GGTA1 that produces a sugar molecule. When a foreign organ is introduced, human antibodies attach to the sugar molecule on the surface of pig cells produced from the action of the GGTA1 molecule, thus killing the organ. With both copies of this gene eliminated, the antibodies cannot attach, halting the early rejection process.

Dr. Robert Hawley and scientists at Immerge, in collaboration with Dr. Kenth Gustafsson, first identified the gene that produces GGTA1 and eliminated, or knocked it out, of the DNA of the cells from the miniature swine. This genetic material was then sent to Dr. Prather’s lab, where Dr. Liangxue Lai and colleagues implanted it into an egg that had its DNA eliminated. The egg was stimulated to begin dividing and was later implanted into a sow. Prather and Immerge announced in January 2002 in the journal Science that they had successfully cloned the world’s first single knock-out miniature swine. The genetic material from these swine was then re-engineered with the aim of knocking out the second copy of this critical gene. These cells were then subjected to another round of nuclear transfer cloning, leading to the birth of the double knock-out piglet on November 18, 2002.

In addition to the modified genetics, the Immerge miniature swine also have other important advantages as potential transplantation candidates.

"The strain of swine we are working with seems to be incapable of transmitting Porcine Endogenous Retrovirus (PERV) to human cells in culture, as we reported in March 2002 in the Journal of Virology," said Julia Greenstein, Ph.D., CEO and President, of Immerge. Unlike other viruses, which can be eliminated either through breeding or raising pigs in a clean lab environment, multiple copies of PERV form part of the normal genomic DNA of pigs and are therefore passed from one generation to the next "Although the risk of any harm posed by PERV to xenotransplant recipients may be purely theoretical, use of this line of miniature swine would help minimize this particular risk of this new technology," said Dr. Greenstein.


The University of Missouri-Columbia has a long-standing research collaboration with Immerge and BioTransplant Incorporated in the field of porcine genetic engineering. This close collaboration has allowed this important research to progress at an accelerated pace. The current collaboration is supported by a National Institutes of Health Small Business Innovative Research grant.

Immerge BioTherapeutics was formed on September 26, 2000, as a joint venture between Novartis Pharma AG and BioTransplant Incorporated. The company, which began operations on January 2, 2001, focuses its research efforts toward developing therapeutic applications for xenotransplantation. The name of the company derives from its use of immunology to address the challenges of conducting transplants between species.

Susan Hayes | EurekAlert!

More articles from Life Sciences:

nachricht Nanoparticle Exposure Can Awaken Dormant Viruses in the Lungs
16.01.2017 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt

nachricht Cholera bacteria infect more effectively with a simple twist of shape
13.01.2017 | Princeton University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Water - as the underlying driver of the Earth’s carbon cycle

17.01.2017 | Earth Sciences

Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

17.01.2017 | Materials Sciences

Smart homes will “LISTEN” to your voice

17.01.2017 | Architecture and Construction

VideoLinks
B2B-VideoLinks
More VideoLinks >>>